Cometriq — Competitive Intelligence Brief

Cometriq (Cabometyx) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor. Area: Oncology.

marketed Kinase Inhibitor Vascular endothelial growth factor receptor 2 Oncology Small molecule

Target snapshot

Cometriq (Cabometyx) — Exelixis. Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cometriq TARGET	Cabometyx	Exelixis	marketed	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Cyramza	RAMUCIRUMAB	Eli Lilly	marketed	Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]	Vascular endothelial growth factor receptor 2	2014-01-01
Cometriq	CABOZANTINIB	Exelixis Inc	marketed	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Nexavar	SORAFENIB	Bayer	marketed	Kinase Inhibitor [EPC]	Vascular endothelial growth factor receptor 2	2005-01-01
Vermox	MEBENDAZOLE		marketed	Anthelmintic [EPC]	Vascular endothelial growth factor receptor 2	1974-01-01
Rivoceranib	Apatinib	Zhongda Hospital	marketed		Vascular endothelial growth factor receptor 2
Ramucirumab (IMC-1211B) DP	Ramucirumab (IMC-1211B) DP	Eli Lilly and Company	phase 3	VEGFR2 inhibitor (monoclonal antibody)	VEGFR2 (Vascular Endothelial Growth Factor Receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2026-08-14 — Cometriq · 7579473 · US
• 2030-01-15 — Cometriq · 11091439 · US
• 2030-01-15 — Cometriq · 11098015 · US
• 2030-01-15 — Cometriq · 11091440 · US
• 2030-10-08 — Cometriq · 8877776 · US
• 2031-07-18 — Cometriq · 10034873 · US
• 2031-07-18 — Cometriq · 10039757 · US
• 2032-02-10 — Cometriq · 11298349 · US
• 2032-02-10 — Cometriq · 9717720 · US
• 2033-07-09 — Cometriq · 9724342 · US

Sponsor landscape (Kinase Inhibitor class)

1. Novartis · 5 drugs in this class
2. Pfizer · 3 drugs in this class
3. Bayer · 2 drugs in this class
4. Boehringer Ingelheim · 2 drugs in this class
5. Hoffmann-La Roche · 1 drug in this class
6. Exelixis Inc · 1 drug in this class
7. Novartis Pharm · 1 drug in this class
8. Osi Pharms · 1 drug in this class
9. Exelixis · 1 drug in this class
10. Roche · 1 drug in this class